parpi for somatic brca1/2 and other dna repair gene mutations in women with metastatic breast cancer
Published 3 years ago • 574 plays • Length 1:52Download video MP4
Download video MP3
Similar videos
-
2:21
a study of talazoparib in somatic brca1/2 mutant mbc identified by cfdna or tumor tissue genotyping
-
6:58
detecting somatic brca1/2 mutations in ovarian cancer
-
3:56
parp inhibitors: activity in brca1 versus brca2 altered mcrpc
-
6:40
overcoming resistance to parpi in brca1-deficient breast cancer with sting agonists
-
7:04
testing for brca germline mutations in the clinic and the mechanism of action of parp inhibitors
-
4:24
the latest treatment options for brca-mutated breast cancer
-
0:48
discover the relationship between parp proteins & brca mutations in cancer development and treatment
-
7:05
how genetic mutations affect metastatic breast cancer disease progression and prognosis
-
9:13
tbcrc 048: olaparib monotherapy in metastatic breast cancer
-
8:08
brca1/2 status and homologous repair deficiency in tnbc
-
4:21
embraca & olympiad: targeting dna repair
-
21:59
palb2
-
2:21
profiling of brca mutations in colorectal cancer
-
2:47
talave: induction talazoparib with parp inhibition in breast cancer
-
49:28
hereditary ovarian cancer – brca and beyond
-
2:47
what is a parp inhibitor? | dana-farber cancer institute | science illustrated
-
3:27
tripathy discusses a study of talazoparib in brca-mutated advanced breast cancer
-
6:05
mechanisms of resistance to parp inhibitor or platinum chemotherapy in brca1/2 mutated metastati...
-
16:22
role of parp inhibitors in prostate cancer